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creativecommons.org/licenses/by-nc-nd/Abstract Aim of study: Incidence rates of melanoma, generated by cancer registries (CRs),
are susceptible to reporting inconsistencies due to increasing decentralisation of diagnosis.
We therefore independently assessed the burden of melanoma in Austria.
Methods: We collected histopathological reports on melanoma of all patients diagnosed in
Austria in 2011. Demographic and clinical characteristics, histopathological tumour stages
were assessed. Their regional distributions and incidence rates were analysed and compared
with data of national and international CRs.
Results: A total of 5246 patients were diagnosed with 1951 in-situ and 3295 invasive mela-
nomas in Austria in 2011 (population 8.4 million). Age, sex and anatomic distribution corre-
sponded to findings in other European countries, however, the incidence of 25/100,000 (world
age-standardised rate) for invasive melanomas was two-fold higher than published by thef Dermatology and Venereology, The Rudolfstiftung Hospital, Juchgasse 25, A-1030 Vienna, Austria. Tel.:
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B. Monshi et al. / European Journal of Cancer 56 (2016) 45e5346Austrian CR (12/100,000). Varying frequencies in diagnosing thin melanomas (1 mm;
n Z 4415) accounted exclusively for significant regional disparities, while advanced tumours
(>1 mm; n Z 761) were evenly distributed. Western Austria showed the highest rates (36/
100,000). Patients from eastern Austria whose melanomas were diagnosed in laboratories in
western Austria (n Z 76) showed significantly higher proportions of in-situ lesions (n Z 43;
57%) compared to those whose tumours were diagnosed in eastern Austria (n Z 4014; in-
situ Z 1369; 34%) (p < 0.0001).
Conclusions: In Austria, the melanoma burden and its potential socio-economic implications
are significantly underestimated. Similarities of incidences indicate this could affect other Eu-
ropean countries with well-established CRs and compromise international comparability of
data. Austrian regional disparities suggest overdiagnosis of thin melanomas due to the vari-
ability of pathologists’ thresholds for the diagnosis of early stage tumours.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The burden of melanoma has been dramatically
increasing since the 1950s [1e6]. Worldwide,
population-based cancer registries (CRs) generate inci-
dence rates and databases for epidemiological research,
cancer prevention, and control [7e10]. Data quality of
CRs entirely depends on the completeness of case
ascertainment, which is estimated by a variety of stan-
dard methods [3,4,7,8,11,12]. However, little is known
about the relative merits and weaknesses of such
methods, and studies on case completeness (CC) at the
level of facilities, where the diagnosis and treatment
occurs, are lacking.[8,11,13,14].
In Austria, the federal statistics agency “Statistics
Austria” runs the national Cancer Registry (CR) and
hospital-based facilities are legally obliged to report all
newly diagnosed cancer cases (Cancer Statistics Act
1969 and Cancer Statistics Ordinance 1978). Since 1983
the Austrian CR has annually published absolute
numbers, incidence rates and trends of malignancies and
investigated its CC on national and regional levels with
internationally recommended methods [15e18]. In 2007
the International Agency for Research on Cancer
(IARC) classified the Austrian data quality as high and
in 2012 the Austrian CR estimated an 94% overall CC
for 2005 [16,19]. In contrast to hospitals, Austrian cli-
nicians in private practice and non-hospital-based pa-
thology laboratories are not legally obliged to report
cancer cases. This might lead to reporting in-
consistencies of melanoma cases as those are frequently
diagnosed in non-hospital settings [13,14]. Still, Statis-
tics Austria, although suspecting that underreporting
influences incidences of various cancer types, assumes
that melanoma patients diagnosed in outpatient settings
would require subsequent hospital-based treatment
leading to their registration [15]. However, this might
not apply to thin melanomas.
TheAustrian CRpublished an incidence rate of 12 new
melanoma cases/100,000 (world age-standardised rate[WSR]) for 2011, implying a 2.5 fold increase since 1983
similar to increments seen in many Western countries
[4,6,15,20,21]. Apart from a true rise in numbers, better
documentation by CRs and raised dermatological sur-
veillancemayunderlie this so called“melanomaepidemic”
[17,18,21,22]. On the other hand, the increased detection
of early tumours associated with rising skin biopsy and
stable disease-specific mortality rates are suggestive of
overdiagnosis of melanoma e defined as diagnosing a
condition that although fulfilling the pathological criteria
for cancer would not go on to cause symptoms and death
e and/or false-positive diagnosis e that is overcalling
benign lesions asmalignant [1,2,22,23].However, research
into these complex and contentious issues on a national
level is challenging and evidence remains scarce.
In this population-based study, we obtained complete
nationwide numbers of all primary melanomas diag-
nosed in Austria in 2011. We quantified the exact
magnitude of melanoma underreporting to the CR and
analysed regional disparities in incidence rates of early
and late stage tumours.
2. Methods
2.1. Study population and data collection
The institutional review board of the city of Vienna
approved the study, a joint-effort of the Austrian Soci-
eties of Dermatology and Pathology. We retrieved all
histopathological reports from the year 2011 containing
the term “melanoma” in their diagnosis section directly
from all hospital- and non-hospital-based pathological
and dermatopathological institutes, registered with the
Austrian Medical Chamber and the Austrian Economic
Chamber, either as hard copies or electronically.
2.2. Inclusion and exclusion criteria
We included only primary melanomas and excluded all
patients with residence abroad, reports on metastases,
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melanoma before 2011, as stated in referral texts.
Furthermore, we excluded reports on biopsies and
incomplete excisions from December 2011 without
documentation of re-excision, as the Austrian CR might
have recorded those in 2012 due to late re-excisions.
To avoid multiple registration of patients with lesions
that were diagnosed and scored by more than one
pathologist, two members of our study team indepen-
dently reviewed all histopathological reports with
similar patient details (first and last name and date of
birth or postcode). If unequivocal, we recorded only
those tumours with the more severe scores. Similarly, we
reviewed all patients diagnosed in 2011 with multiple
synchronous or metachronous melanomas, defined by
equivocal different anatomic localisation and/or
morphology.
For incidence analysis of primary cutaneous in-situ
(D03 e WHO International Classification of Diseases,
2014) and invasive melanomas (C43), we followed the
general recommendations of the IARC and counted
only one tumour per patient [24]. In case of multiple
primary melanomas, only the first melanoma or, if
diagnosed simultaneously, the thicker or, in case of
equal thickness, the one with more valid information
entered incidence analysis.
2.3. Recorded data
We recorded the postcode of patients and/or referring
physicians, diagnosing institution, date of sign-out, sex,Fig. 1. The study’s flow chart of histopathological reports with the te
lesions excluded from and included in the incidence analysis.age, anatomic localisation, melanoma subtype as indi-
cated in the report, Breslow tumour thickness, Clark
level, histopathological tumour stage according to the
American Joint Committee against Cancer, regression,
numbers of mitosis/mm2, ulceration, microsatellitosis,
and completeness of excision. Austrian census data and
CR’s data were retrieved from the homepage of the
Statistics Austria [15]. International incidence rates for
2012 were derived from the GLOBOCAN homepage
[25]. Considering the coverage area of pathology labo-
ratories we allocated Austrian States to four regions:
eastern (Vienna, Burgenland, and Lower Austria),
central-northern (Upper Austria and Salzburg), central-
southern (Styria and Carinthia), and western Austria
(Tyrol and Vorarlberg).
2.4. Statistical analysis
Mean with standard deviation or median with inter-
quartile range was calculated for quantitative variables,
whereas qualitative variables were described using ab-
solute and relative frequencies. Chi-square tests were
used to compare proportions. We calculated Man-
teleHaenszel age-adjusted risk ratios (MH RR) and
95% confidence intervals to compare incidence rates
between sexes. A linear regression, with age and sex as
independent variables, yielded estimates of the impact of
sex on tumour thickness and the average increase in
tumour thickness with age. Age-standardised incidence
rates were based on the revised European standard
population of 2013 and the Segi world standardrm “melanoma” in their diagnosis section displaying numbers of
Table 1
Overview of cutaneous in-situ and invasive melanomas in Austria in
2011
In-situ melanoma Invasive melanoma
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of the national CR were calculated under the assump-
tion that our data represented the total number of
melanomas diagnosed in Austria.
n (%) n (%)
Total 1951 (100) 3295 (100)
Age groups (years)a
0e14 4 (0) 12 (0)
15e24 56 (3) 77 (2)
25e34 172 (9) 246 (8)
35e44 286 (15) 454 (14)
45e54 343 (18) 574 (17)
55e64 348 (18) 547 (17)
65e74 395 (20) 723 (22)
75e84 261 (13) 454 (14)
85þ 86 (4) 206 (6)
Age at diagnosis (years)
Mean  SD 57  18 59  29
Sexa
Men 925 (47) 1656 (50)
Women 1026 (53) 1639 (50)
Breslow thickness
Men e median (IQR) NA 0.6 (0.4e1.1)
Women e median (IQR) NA 0.5 (0.4e0.9)
Anatomic site e menb
Trunk 477 (52) 1019 (63)
Head and neck 211 (23) 251 (15)
Lower extremities 111 (12) 183 (11)
Upper extremities 96 (11) 148 (9)
Other sitesd 19 (2) 29 (2)
Anatomic site e womenc
Trunk 312 (31) 566 (35)
Head and neck 243 (24) 215 (13)
Lower extremities 307 (30) 507 (32)
Upper extremities 133 (13) 281 (18)
Other sitesd 19 (2) 37 (2)
Diagnosing facility
Hospital-based 876 (45) 1583 (48)
Non-hospital-based 1075 (55) 1712 (52)
SD Z standard deviation; NA Z not applicable; IQR Z 1st to 3rd
quartile.
Percentages were rounded-off to whole numbers.
a In two invasive cases no age was specified.
b In men anatomic localisation was not provided in 11 in-situ and 26
invasive cases.
c In women anatomic localisation was not provided in 12 in-situ and
33 invasive cases.
d Other comprises melanomas on acral and genital epidermal areas.3. Results
All 53 Austrian hospital- and non-hospital-based pa-
thology and dermatopathology laboratories took part in
the study and a complete list is provided at the end of
the discussion section of the manuscript. Four labora-
tories did not diagnose any melanoma in 2011 and from
the remaining 49 we gathered 7783 reports (Fig. 1, Table
1). After exclusion of 2537 reports, incidence analyses
were based on 5246 patients with 1951 in-situ and 3295
invasive melanomas and compared to 716 in-situ and
1534 invasive melanomas registered by the Austrian CR
for the same year (Fig. 2, Table 2). Histopathologic
staging of tumours was provided in 5176 patients, but
lacked sufficient data for classification into sub-stages a/
b. The vast majority (n Z 4415; 84%) were early stage
melanomas (Tis and T1) equally occurring in both sexes
(MH RR Z 1.1 [1.0e1.1]; p Z 0.06). In contrast, mel-
anomas with a Breslow thickness of >4 mm (T4)
(n Z 149; 3%) affected significantly more men (MH
RRZ 2.3 (1.7e3.2); p < 0.0001). Breslow thickness did
not differ in men and women (p Z 0.40) and increased
significantly with age (p < 0.0001) at an estimated rate
of 0.07 mm per year. Melanoma incidence rose consid-
erably with age and all age groups were evenly under-
represented in official estimates (Fig. 2). By compilation
of virtually 100% of all newly diagnosed melanomas in
Austria in 2011 we found that the CR’s CC varied
markedly between Austrian States from 14% for Vienna
to more than 90% for Tyrol and Carinthia (Table 3) [15].
Comparison of the study’s incidence rates (25/100,000
WSR for men and women) with estimates from GLO-
BOCAN for selected countries suggested that Austria
had the highest melanoma incidence in Europe and the
third highest worldwide behind Australia (41 and 30)
and New Zealand (39 and 33) (Fig. 3). This contrasting
juxtaposition emphasises the impact of different meth-
odological approaches in case retrieval, adopted by us
and by various CRs, on the comparability of interna-
tional data.
Austrian pathology laboratories generated the inci-
dence rates of the regions in which they were situated by
diagnosing the vast majority of patients, who were living
in this region (Fig. 4). Austrian regional incidences of
melanoma increased gradually from east to west, which
was solely attributable to different incidence rates of Tis
and T1 tumours. In contrast, incidences of T2 to T4
tumours were evenly distributed throughout Austria
(Table 4, Fig. 5). Even after exclusion of in-situ lesions
we noted significantly higher proportions of early inva-
sive T1 melanomas in western and southern-centralAustria (443; 80% and 627; 77%, respectively)
compared to eastern Austria (825; 70%) (p < 0.0001).
Apart from regional factors, varying pathologists’
thresholds for diagnosing thin melanomas might addi-
tionally underlie higher melanoma incidences in western
Austria. To elucidate this question we excluded patients
from western Austria and with them possible con-
founding factors like higher UV radiation from further
analysis [21,26]. This revealed that the proportion of
thin melanomas in the population, living in the rest of
Austria (n Z 4090), was significantly depending on the
diagnosing laboratory. Those patients whose tumours
were diagnosed by pathology laboratories located in
western Austria (n Z 76) comprised a significantly
Fig. 2. Comparison of official CR’s (dashed lines) and our incidence rates (solid lines) of in-situ and invasive melanoma in men and women
according to age groups in Austria in 2011. Completeness of the CR’s incidence data are depicted underneath each graph. CI, confidence
interval.
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to those, whose tumours were diagnosed by laboratories
situated in the rest of Austria (n Z 4014; 34%)
(p < 0.0001). We found no correlation between inci-
dence rates of Tis, Tis/T1 or Tis-T4 melanomas and the
density of dermatologists in private practice in Austrian
States (Fig. 6).
4. Discussion
The precise estimation of the genuine melanoma inci-
dence is indispensable for epidemiological research and
for calculating health care budgets, particularly with
the emergence of costly therapeutic options forTable 2
Incidence rates of in-situ and invasive malignant melanoma in Austria in 2
Incidence rates per 100,000
Crude
Total Men Women
In-situ and invasive melanoma 63 63 62
In-situ melanoma 23 23 24
Invasive melanoma 39 41 38
ESR Z European age-standardised incidence rate; WSR Z world age-stan
Total rates (crude, ESR, and WSR) for in-situ and invasive melanomas arprogressive disease like immunomodulatory drugs. We
demonstrate that in Austria the burden of melanoma is
grossly underestimated as official incidence rates
lacked 64% (n Z 1235) in-situ and 54% (n Z 1761)
invasive melanomas in 2011. One reason for under-
reporting melanoma to CRs is the increasing shift of
diagnosis and treatment to non-hospital-based facil-
ities, which applied to 53% of patients in our study
[3,13,14]. It is most likely that the Austrian CR missed
a substantial number of these lesions because cancer
reporting is not legally mandatory for non-hospital-
based facilities and the CR depends ‘passively’ on
case notifications [15]. However, four regional regis-
tries in western Austria adopted more “active”011
ESR WSR
Total Men Women Total Men Women
64 70 60 39 39 41
24 25 23 15 14 16
40 45 37 25 25 25
dardised incidence rate.
e bold. Incidence rates were rounded to whole numbers.
Table 3







Austria e total 1534 (18) 3295 (39) 47
Burgenland 18 (6) 45 (16) 40
Vienna 98 (6) 686 (40) 14
Lower Austria 212 (13) 449 (28) 47
Upper Austria 265 (19) 564 (40) 47
Salzburg 71 (13) 200 (38) 36
Styria 160 (13) 554 (46) 29
Carinthia 223 (40) 246 (44) 91
Tyrol 390 (55) 422 (60) 92
Vorarlberg 97 (26) 129 (35) 75
The incidence rates are provided in brackets, CC denotes the Austrian
Cancer Registry’s (CR) case completeness. Incidence rates were
rounded to whole numbers.
Fig. 4. Numbers of patients/melanomas diagnosed within or
outside the region of their residence. Light grey identifies patients
whose melanomas were diagnosed by pathology laboratories of
their own region. Dark grey those, whose melanomas were diag-
nosed by pathology laboratories situated outside their region.
Eastern Z Austrian States of Vienna, lower Austria, Burgenland;
central-southern Z Austrian States of Styria and Carinthia; cen-
tral-northern Z Austrian States of Upper Austria and Salzburg;
western Z Austrian States of Tyrol and Vorarlberg.
B. Monshi et al. / European Journal of Cancer 56 (2016) 45e5350methods of case retrieval and provided their data to the
national CR. This influenced Austrian data in two
ways: (1) western Austrian States displayed higher
official melanoma rates than their eastern counter-
parts, which lack own regional CRs and (2) as shown
by comparison with our study’s results, CC of official
data is significantly higher for western than for eastern
Austrian States [15,27].
The alarming number of newly diagnosed, yet
unrecognised, melanomas in Austria may imply serious
consequences. On the one hand it suggests that under-
reporting affects national and international melanoma
incidence rates, time trends and their comparability far
more than previously estimated, as: (1) Statistics Austria
like many other well-established CRs follows standards
of the IARC [15,19,24,28]; (2) population-based mela-
noma incidence rates of countries like France and
Germany match Austrian official figures [5,25]; (3)
“active” data retrieval in our study yielded 50% higher
melanoma rates for Austria than GLOBOCANFig. 3. Effects of different methods of case ascertainment, as applied b
the Austrian incidence rates in the context of international figures. Esti
2012 were derived from GLOBOCAN.projected for the United States, thus indicating the po-
tential scale of melanoma underreporting [3,13,14,25];
(4) melanoma incidences vary grossly among United
States from 12/100,000 (WSR) in Texas to 34/100,000 in
Utah [13,20,21,25].
On the other hand reporting inconsistencies of large
proportions of thin melanomas with an excellent prog-
nosis may also impact the comparability of international
melanoma-specific survival data and account for the
relatively low, recently published, Austrian survival
rates [10,29].
Analysis of the regional distribution of Austrian
incidence rates in our study revealed 33 invasive mela-
nomas/100,000 (European age-standardised rate [ESR])y the Austrian CR (Austria) and by us (AUSTRIA [STUDY]) on
mates (including official Austrian figures) for selected countries for
Table 4







ESR WSR ESR WSR ESR WSR ESR WSR
In-situ melanomas 15 9 18 10 29 19 52 36
Invasive melanomas 33 19 45 26 40 26 53 36
European (ESR) and world age-standardised rates (WSR)/100,000.
Incidence rates were rounded to whole numbers.
Fig. 6. Correlation of the incidence rates of melanomas with the
density of dermatologists in private practice within the nine Aus-
trian States.
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(ESR) in the Cantons of Zurich and Zug/Switzerland in
2011 documented by their regional CR (personal
communication). Remarkably, incidences gradually
increased westwards and western Austria showed by far
the highest numbers with 53/100,000 (ESR). Possible
explanations are a higher UV exposure in western
mountainous areas, differing recreational activities or
earlier detection by patients and doctors due to a higher
population’s awareness of skin self-examination [21,26].
However, we demonstrate that (1) these regional dis-
parities were exclusively attributable to differences in
numbers of early (Tis/T1) melanomas and that (2) pa-
thology laboratories in western Austria accounted for
the incidence rates of western Austria. They diagnosed
higher proportions of thin melanomas compared to
laboratories in the rest of Austria, which was still sig-
nificant after exclusion of regional confounding factors
indicating overdiagnosis and/or false-positive diagnosis
of thin melanomas. Indeed experts regard the lack of
firm pathologic criteria for the diagnosis of early mela-
nomas as one of the greatest challenges in dermatopa-
thology [2,22]. It is therefore conceivable that a
significant variability in pathologists’ thresholds for the
interpretation of the biologic behaviour of thinFig. 5. Distribution of melanomas (crude incidence rates) according
south, and western Austria as well as for whole Austria.melanocytic lesions contributed to the observed regional
trends [2,22].
Certain findings of our study warrant a more critical
evaluation. First, we lacked access to data prior to 2011;
therefore, we cannot completely rule out that patients
with a history of melanoma before 2011 were included in
the incidence analysis. Based on data, which specified a
1% per year risk of Californian melanoma patients to
develop secondary primary melanomas and on official
Austrian incidence rates from 2001 to 2010, we calcu-
lated that this might apply to a maximum of 150 pa-
tients in our cohort [30]. However, exclusion of those
would only marginally change our incidence of invasive
melanoma from 39 to 37/100,000 (crude rate) and
underreported cases would still be significant. Addi-
tionally, these differences are probably much lower, due
to our efforts to exclude such patients in the first place.
Secondly, we could not analyse the influence of skinto their tumour stage (Tis-T4) for eastern, central-north, central-
B. Monshi et al. / European Journal of Cancer 56 (2016) 45e5352biopsy rates on national and regional melanoma in-
cidences [1]. Indeed, the high numbers of Austrian der-
matologists in private practice, accounting for 53% of all
melanoma specimens in 2011, may lead to more frequent
skin biopsies and higher incidence rates. Yet, we could
not find any association between the density of derma-
tologists and the melanoma incidence rates in Austrian
states. Thirdly, the study was not designed to investigate
overdiagnosis, which is particularly challenging in the
context of thin melanomas, which have, once excised an
excellent prognosis. However, the even regional distri-
bution of melanoma-specific mortality rates ranging
from 2.0 to 2.4 throughout Austria further supports our
hypothesis that melanoma overdiagnosis adds to the
disease burden [15,23]. Finally, our results may not be
generalised to countries beyond central Europe due to
potential differences of population behaviour, genetic
and demographic make-up, environmental factors, spe-
cific legal frameworks as well as pathologists’ and der-
matopathologists’ training programmes.
In conclusion, we revealed an alarming, yet unrec-
ognised, number of melanomas in Austria in 2011.
Similarities in incidence rates suggest this might also
affect other Western countries with well-established
CRs. The consequences are underestimation of the true
melanoma burden with its socio-economic implications
and reduced international comparability of incidence
and survival data [5,21,29]. Our results highlight the
need to adjust the Austrian legal framework for
reporting cancer cases to the CR and may help to foster
its data quality as it has been shown that CRs perform
better in terms of CC when their data is used in etio-
logical or clinical research [10]. Moreover, we show,
that CC is significantly enhanced by “active” retrieval
of a single case-finding source such as histopathological
reports from hospital- and non-hospital-based facilities
[7]. Finally, significant regional trends in numbers of
thin melanomas may at least in part indicate over-
diagnosis and/or false-positive diagnosis and empha-
sises the impact of pathologists’ thresholds for the
diagnosis of early melanomas on overall incidence
rates.
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